Drug Profile
Autologous stem cell therapy - Biotech Holdings
Alternative Names: Microbiome optimized autologous stem cells - Biotech Holdings; ProCell activated stem cells - Biotech HoldingsLatest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Biotech Holdings
- Class Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements; Hepatocyte growth factor modulators; Immunosuppressants; Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Peripheral vascular disorders
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral, Injection)
- 28 Aug 2020 No recent reports of development identified for clinical-Phase-Unknown development in Peripheral-vascular-disorders in USA (Parenteral)
- 25 Oct 2017 Biotech Holdings and Biorasi agree to co-develop stem cell therapy for critical limb ischaemia